Roche CD20xCD3 Bispecific Antibody Mosunetuzumab Treatment Of Follicular Lymphoma, FDA Breakthrough Treatment Designation
-
Last Update: 2020-07-16
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Roche announced its CD20xCD3 bispecific antibody mosunetuzumab for recurrent or refractive (R/R) follicular lymphoma patients, who have previously received at least two systemic therapies, granted a breakthrough treatment designation (BTD) by the U.SFood and Drug Administration (FDA)!----Roche's 2:1 T-cell bispecific antibodies (Photo: Roche's official website) Mosunetuzumab is a CD20xCD3 T-cell bispecific antibody that targets CD20 and T cell surfaces of B cells, activates and redirects T cells through dual targeting, and releases cytotoxic proteins to destroy target B cellsMosunetuzumab has a structure similar to that of natural human antibodies, with two "Fab" regions, but unlike naturally occurring antibodies, because one "Fab" region targets CD20 and the other "Fab" region targets CD3is currently being clinically developed as a monotherapy or in combination with other drugs to treat CD20-positive B-cell non-Hodgkin's lymphoma patientsI/Ib phase GO29781 study showed that mosunetuzumab had a high response rate and achieved long-lasting complete remission in patients with relapsed or refractive non-Hodgkin's lymphomaFDA awarded the BTD title based on the results
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
